QED Therapeutics Competitors, Revenue, Alternatives and Pricing
Overview
Industry Ranking
Estimated Revenue & Financials
- QED Therapeutics's estimated annual revenue is currently $9.9M per year.
- QED Therapeutics received $65.0M in venture funding in January 2018.
- QED Therapeutics's estimated revenue per employee is $155,000
Employee Data
- QED Therapeutics has 64 Employees.
- QED Therapeutics grew their employee count by 100% last year.
- QED Therapeutics currently has 4 job openings.
QED Therapeutics Competitors
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
| $7M | 45 | 10% | N/A | - | N/A | |
| N/A | 205 | N/A | N/A | - | N/A | |
| $46.8M | 302 | 4% | N/A | - | N/A | |
| $22.3M | 144 | N/A | N/A | - | N/A | |
| $44.3M | 286 | N/A | N/A | - | N/A | |
| $101.2M | 653 | 46% | N/A | - | N/A | |
| $33.3M | 215 | 3% | N/A | - | N/A | |
| $28.7M | 185 | 8% | N/A | - | N/A | |
| $39.4M | 254 | N/A | N/A | - | N/A | |
| $6.5M | 42 | 14% | N/A | - | N/A |
What Is QED Therapeutics?
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
keywords:N/A64
Number of Employees
$9.9M
Revenue (est)
4
Current Jobs
100%
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
N/A
Type
QED Therapeutics News
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the ...
SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of data demonstrating the clinical ...
Sarepta Therapeutics is also focused on the disease. ... comes about a year after BridgeBio launched QED Therapeutics to develop infigratinib, ...
QED Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-01-31 | $65.0M | Undisclosed | BridgeBio Pharma | Article |